Time for Gilead Sciences-Heavy ETFs?

03:05pm, Tuesday, 12'th Sep 2023
Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.
Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.

3 Dividend Stocks for September 2023

12:00pm, Saturday, 09'th Sep 2023
#Morningstar  #PfizerStock #DividendStocks Dividend investors: Put these cheap stocks on your buy list. 00:00 Introduction 00:28 Pfizer PFE 01:03 Medtronic MDT 01:34 Gilead Sciences GILD Susan Dziub
Wall Street underestimates the prospects of Pfizer and Gilead Sciences, given their significant role in developing vaccines and medicines against COVID-19. Gilead Sciences' revenue has remained stable

Bank of America says buy Gilead

02:31pm, Friday, 08'th Sep 2023
The "Halftime Report" traders debate the biggest analyst calls of the day.
BofA upgraded shares of biotech Gilead to Buy from Neutral, and lifted the target price to $95 from $88.
Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo Healthcare Conference September 6, 2023 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit

Call of the day: The health care trade

01:30pm, Wednesday, 06'th Sep 2023
CNBC's Halftime traders Steve Weiss, Liz Young, Joe Terranova, and Brian Belski discuss the call of the day: health care.
Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and a l
Drugmakers are often great dividend payers, and AbbVie and Gilead are among the best. AbbVie sales are currently dropping, but that shouldn't last for too long.
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.
Gilead Sciences (NASDAQ: GILD ) stock is on the move Thursday following FDA approval for its Veklury Covid-19 treatment. This saw the FDA approve the company's supplemental new drug application (sNDA)
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Healthcare Co
Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%,
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE